Invivoscribe, a world leader in developing and providing internationally standardized assay kits and services in support of precision medicine and a proven leader in Companion Diagnostics (CDx) development and commercialization announced today that it will be presenting at Biotech Showcase 2019, January 7–9, 2019, at the Hilton Union Square, San Francisco, CA.
Jeffrey E. Miller, Ph.D., CEO & CSO of Invivoscribe, Inc., will discuss Invivoscribe’s Streamlined CDx™ model which has proven successful in accelerating FDA, EMA and PMDA approvals of new targeted therapies. He will also be available to participate in one-on-one meetings with a number of potential partners who are registered to attend this conference and also interested parties attending the JP Morgan Conference being concomitantly held in San Francisco.
Information for Invivoscribe’s presentation are as follows:
Date: Monday, January 7, 2019
Time: 8:45 am PST
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
“We are delighted that Invivoscribe will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great strategic networking opportunity of 2019.”
Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics™. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
To arrange an investor or a business development meeting with Invivoscribe during the conference please contact, Michael Vishnevetsky, Invivoscribe’s Head of Global Business Development, at firstname.lastname@example.org, or contact Invivoscribe at email@example.com or visit www.jp.invivoscribe.com.